세계 혈관 내피 성장인자 수용체(VEGFR) 억제제 시장 규모는 2024년 141억 2,000만 달러에서 2033년에는 223억 4,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 예측 기간 동안 5.9%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상됩니다.
혈관 내피 성장인자(VEGF) 및 혈관 내피 성장인자 수용체(VEGFR) 억제제는 VEGF 및 VEGFR의 활성을 억제하는 치료제로, 혈관신생(기존 혈관에서 새로운 혈관이 형성되는 것)에 중요한 역할을 합니다. 암 진행, 퇴행성 안질환, 염증성 질환 등 다양한 생리적, 병리적 과정에 중요합니다.
암에서는 비정상적인 혈관 신생이 종양의 성장과 전이를 촉진하기 때문에 VEGF/VEGFR 억제제는 이러한 경로를 차단하는 것이 중요합니다. 이러한 억제제에는 VEGF 자체를 표적으로 하는 단일클론항체(예: 베바시주맙)와 VEGFR을 표적으로 하는 티로신 키나아제 억제제(TKI)(예: 파조파닙)가 있습니다. 이들 약제는 신세포암, 대장암, 간세포암 등 다양한 암 치료에 널리 사용되고 있습니다.
티로신키나아제 억제제(TKI)는 가장 일반적인 VEGFR 억제제로 혈관신생과 종양 증식에 필요한 세포 내 신호전달을 차단합니다. 대표적인 예로는 파조파닙, 수니티닙, 카보잔티닙 등이 있습니다. 단클론항체(mAbs) 억제제는 VEGF 분자 또는 그 수용체에 직접 결합하여 VEGF가 혈관신생을 유발하는 것을 차단합니다. 베바시주맙과 같은 약물이 이 범주에 속합니다.
혈관 내피 성장인자 수용체(VEGFR) 억제제 시장은 암의 발병률과 유병률 증가가 세계 시장 성장을 크게 견인하고 있으며, 예측 기간 동안에도 시장 성장을 견인할 것으로 예상됩니다. 암은 전 세계적으로 주요 사망 원인 중 하나이며, 고령화, 생활습관 변화, 환경적 영향 등의 요인으로 인해 발병률이 증가할 것으로 예상됩니다.
예를 들어, 2022년 Globocan 데이터에 따르면 남성의 암 발병률은 1,030만 명, 여성은 970만 명이며, 2025년에는 남성 1,250만 명, 여성 1,160만 명에 달할 것으로 예측됩니다. 전 세계 암 발병률이 지속적으로 증가함에 따라 VEGFR 억제제를 포함한 효과적인 치료 옵션에 대한 수요가 급증하고 있습니다.
또한, 업계 주요 기업들은 이 시장 성장의 원동력이 될 제품 출시 및 승인을 발표했습니다. 예를 들어, 2023년 11월 HUTCHMED는 다케다가 화학요법과 항VEGF 치료를 받은 성인 전이성 대장암(mCRC) 치료제로 FRUZAQLA(fruquintinib)의 미국 FDA 승인을 받았다고 발표했습니다. 이번 승인은 프루킨티닙이 이전 치료 경험이 있는 전이성 결장직장암 환자의 전체 생존기간(OS)과 무진행 생존기간(PFS)을 유의미하게 개선하는 것으로 나타난 3상 임상 FRESCO-2 데이터를 기반으로 합니다. 이러한 모든 요인들이 세계 혈관 내피 성장인자 수용체(VEGFR) 억제제 시장에 대한 수요를 창출하고 있습니다.
높은 치료비용은 혈관 내피 성장인자 수용체(VEGFR) 억제제 세계 시장 성장을 저해하고 있습니다. 티로신 키나아제 억제제(TKI)와 단클론항체를 포함한 VEGFR 억제제는 복잡한 개발 과정, 높은 제조 비용, 치료의 특수성으로 인해 가장 고가의 암 치료제 중 하나입니다. 이러한 경제적 부담은 특히 신세포암, 대장암, 간세포암과 같이 지속적인 관리가 필요한 암의 경우 치료 기간이 길기 때문에 더욱 가중됩니다.
높은 비용의 주요 요인은 이러한 약물을 시장에 출시하기 위해 필요한 연구개발(R&D) 투자입니다. 예를 들어, 베바시주맙 단독요법과 같은 약제는 11년간 개별 치료비용이 14,772달러, 사회적 수익은 357,680달러로 투자수익률(ROI)이 2,421%라는 놀라운 결과를 가져왔습니다. 반면, 라니비주맙 치료는 106,582달러로 265,870달러의 사회적 수익(ROI 249%), 아플리버셉트 치료는 61,811달러로 310,611달러의 사회적 수익(ROI 503%)을 가져왔습니다. 11년간 총 285억 달러의 사회적 이익은 베바시주맙이 242억 달러(약 85%), 라니비주맙이 7억 달러(2.5%), 아플리버셉트가 36억 달러(12.6%)로 추산됩니다. 따라서 위의 요인들이 세계 혈관 내피 성장인자 수용체(VEGFR) 억제제 시장의 잠재적 성장을 제한하고 있을 가능성이 있습니다.
세계의 혈관내피성장인자 수용체(VEGFR) 억제제(VEGFR) 시장에 대해 조사했으며, 시장 개요와 함께 유형별/약제 유형별/용도별/투여 경로별/지역별 동향, 경쟁 구도, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.
The global vascular endothelial growth factor receptor (VEGFR) inhibitors market reached US$ 14.12 billion in 2024 and is expected to reach US$ 22.34 billion by 2033, growing at a CAGR of 5.9 % during the forecast period of 2025-2033.
Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors are therapeutic agents that block the activity of VEGF and VEGFR, which play a key role in angiogenesis, the formation of new blood vessels from existing ones. VEGF and VEGFR signaling is critical for various physiological and pathological processes, including cancer progression, degenerative eye conditions, and inflammatory diseases.
In cancer, abnormal angiogenesis facilitates tumor growth and metastasis, making VEGF/VEGFR inhibitors important in blocking these pathways. These inhibitors include monoclonal antibodies that target VEGF itself (e.g., bevacizumab) and tyrosine kinase inhibitors (TKIs) that target VEGFR (e.g., pazopanib). These drugs are widely used to treat different cancers, such as renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma, among others.
Tyrosine kinase inhibitors (TKIs) are the most common VEGFR inhibitors, which block the intracellular signaling required for angiogenesis and tumor growth. Common examples include pazopanib, sunitinib, and cabozantinib. Monoclonal antibody (mAbs) inhibitors directly bind to the VEGF molecule or its receptor, preventing it from triggering angiogenesis. Drugs like bevacizumab fall into this category.
Market Dynamics: Drivers & Restraints
Rising Incidence and Prevalence of Cancer
The rising incidence and prevalence of cancer are significantly driving the growth of the global vascular endothelial growth factor receptor (VEGFR) inhibitors market and are expected to drive it throughout the market forecast period. Cancer is one of the leading causes of death worldwide, and its incidence is expected to rise due to factors such as aging populations, lifestyle changes, and environmental influences.
For instance, according to the globocon data in 2022, the cancer incidence for males was 10.3 million, while for females, it was 9.7 million. By 2025, the cancer incidence is projected to reach 12.5 million for males and 11.6 million for females. As the global cancer burden continues to increase, the demand for effective treatment options, including VEGFR inhibitors, has surged.
Additionally, key players in the industry have announced product launches and approvals that would drive this market growth. For instance, in November 2023, HUTCHMED announced that Takeda has received U.S. FDA approval for FRUZAQLA (fruquintinib) to treat metastatic colorectal cancer (mCRC) in adults who have already undergone prior chemotherapy and anti-VEGF treatment. The approval is based on data from the Phase 3 FRESCO-2 trial, which demonstrated that fruquintinib significantly improves both overall survival (OS) and progression-free survival (PFS) in patients with previously treated mCRC. All these factors demand the global vascular endothelial growth factor receptor (VEGFR) inhibitors market.
High Cost of Treatment
The high cost of treatment will hinder the growth of the global vascular endothelial growth factor receptor (VEGFR) inhibitors market. VEGFR inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, are among the most expensive cancer therapies due to their complex development processes, high manufacturing costs, and the specialized nature of the treatments. This financial burden is exacerbated by the long duration of treatment, especially in cancers that require ongoing management, such as renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma.
A key factor contributing to the high costs is the research and development (R&D) investment needed to bring these drugs to market. For instance, drugs like Bevacizumab monotherapy had an individual treatment cost of $14,772 over 11 years, with a societal return of $357,680, resulting in an impressive 2,421% return on investment (ROI). In comparison, ranibizumab therapy cost $106,582, yielding a societal return of $265,870 (249% ROI), while aflibercept treatment cost $61,811 and generated $310,611 in societal returns (503% ROI). For the 2018 NVAMD treatment cohort, the total 11-year societal gain was estimated at $28.5 billion, with $24.2 billion (about 85%) attributed to bevacizumab, $0.7 billion (2.5%) to ranibizumab, and $3.6 billion (12.6%) to aflibercept. Thus, the above factors could be limiting the global vascular endothelial growth factor receptor (VEGFR) inhibitors market's potential growth.
The global vascular endothelial growth factor receptor (VEGFR) inhibitors market is segmented based on type, drug type, application, route of administration, and region.
The tyrosine kinase inhibitor (TKI) segment in the drug type is expected to dominate the global vascular endothelial growth factor receptor (VEGFR) inhibitors market
The tyrosine kinase inhibitor (TKI) segment plays a crucial role in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market, largely driven by the increasing demand for targeted cancer therapies. TKIs block VEGFR signaling, which is essential for angiogenesis, the process of forming new blood vessels that support tumor growth and metastasis. By targeting this pathway, TKIs help limit the blood supply to tumors, inhibiting their growth and spread. This has made them particularly effective in treating various cancers, such as renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma.
Notable TKIs in the VEGFR inhibitor market include pazopanib, sunitinib, cabozantinib, lenvatinib, and regorafenib. These drugs are designed to specifically block VEGFR and interfere with the angiogenesis process, thereby preventing tumors from forming the blood vessels they need to grow. The TKI segment has been strengthened by strong clinical trial data, showing that these inhibitors are effective both as monotherapies and in combination with other cancer treatments. This has expanded their use across multiple cancer types, boosting their market demand.
Additionally, key players in the industry's product launches and approvals would drive this segment growth in the market. For instance, in December 2023, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg) for the treatment of advanced renal cell carcinoma (RCC) in patients who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). These factors have solidified the segment's position in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market.
North America is expected to hold a significant position in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market share
North America holds a substantial position in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market and is expected to hold most of the market share. The increasing prevalence of diseases such as cancer, which require targeted treatments to inhibit angiogenesis, is driving the growing demand for VEGFR inhibitors. These therapies, which disrupt the formation of blood vessels that support tumor growth, are becoming essential in managing various cancers, thus leading to a significant rise in their market adoption.
According to the National Institutes of Health (NIH) data in May 2024, cancer has a significant impact on society both in the United States and globally. Cancer statistics offer insight into the scope of the disease and reflect its burden on society. In 2024, it is estimated that 2,001,140 new cases of cancer will be diagnosed in the United States, and 611,720 people will succumb to the disease. The escalating incidence of cancer underscores the urgent need for VEGFR inhibitor solutions.
Both the U.S. and Canada have significantly increased their investments in healthcare research and development (R&D), which has played a pivotal role in advancing VEGFR-targeted therapies. This enhanced financial support is expected to continue driving market growth in the coming years.Furthermore, the adoption of cutting-edge medical technologies, including advanced diagnostic tools, is accelerating the use of VEGFR inhibitors. As healthcare providers increasingly incorporate these technologies into personalized treatment plans, the demand for these therapies is growing, contributing to the overall expansion of the market.
In this region, a major number of key players are present, with well-advanced healthcare infrastructure, government initiatives, and product approvals that would drive this market growth. For instance, in October 2024, Elevar Therapeutics announced the acceptance of its New Drug Application (NDA) for rivoceranib, in combination with camrelizumab, by the U.S. FDA. This combination therapy is being proposed as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC), a form of liver cancer. Thus, the above factors are consolidating the region's position as a dominant force in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market.
The major global players in the vascular endothelial growth factor receptor (VEGFR) inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Biocon, Exelixis, Inc., Bayer AG, Eisai Co., Ltd., Takeda Pharmaceuticals U.S.A., Inc., Sanofi (Regeneron Pharmaceuticals, Inc.), AVEO Pharmaceuticals, Inc., Eli Lilly and Company, and Genentech USA, Inc. among others.
The global vascular endothelial growth factor receptor (VEGFR) inhibitors market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE